Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
Infect Immun. 2012 Apr;80(4):1314-22. doi: 10.1128/IAI.06081-11. Epub 2012 Jan 30.
Antibodies to pneumococcal capsular polysaccharide (PPS) are required for PPS-based vaccine-mediated protection against Streptococcus pneumoniae. Previous work established that 1E2, a mouse IgG1 to PPS3 that does not induce serotype 3 (ST3) S. pneumoniae killing by phagocytes in vitro, protects mice from death after intranasal infection with ST3, but its efficacy was abrogated in FcγR (F common gamma receptor)-deficient mice. In this study, we determined whether 1E2 efficacy against pulmonary ST3 infection requires FcγRIII. 1E2 did not protect FcγRIII-deficient (FcγRIII(-/-)) mice. Studies of the mechanism of 1E2-mediated effects showed that it resulted in a marked reduction in lung inflammation in ST3-infected wild-type (Wt [C57BL/6]) mice that was abrogated in FcγRIII(-/-) mice. 1E2 had no effect on early bacterial clearance in the lungs of ST3-infected Wt, FcγRIIB(-/-), or FcγRIII(-/-) mice, but it reduced levels of bacteremia and serum macrophage inflammatory protein-2) (MIP-2), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) in Wt and FcγRIIB(-/-) mice, strains in which it is protective. As previous work showed that neutrophils were dispensable for 1E2 efficacy, we investigated whether macrophages are required for 1E2 efficacy against intranasal infection with ST3 and found that its efficacy was abrogated in Wt mice depleted of macrophages intranasally. In vitro studies revealed that1E2 promoted ST3 internalization by naïve alveolar macrophages but did not induce early intracellular killing. Macrophages from 1E2-treated ST3-infected mice studied ex vivo exhibited more apoptosis than those from FcγRIII(-/-) mice. These findings suggest that 1E2 mediates protection against ST3 in mice by affecting the inflammatory response, perhaps in part via macrophage apoptosis, rather than by inducing early bacterial clearance.
针对肺炎球菌荚膜多糖(PPS)的抗体是基于 PPS 的疫苗介导对抗肺炎链球菌(Streptococcus pneumoniae)保护所必需的。先前的工作表明,1E2 是一种针对 PPS3 的小鼠 IgG1,它不会诱导吞噬细胞在体外杀死 3 型(ST3)肺炎链球菌,但它可以保护小鼠免受 ST3 鼻内感染后的死亡,但在 FcγR(F 共同γ受体)缺陷小鼠中其功效被削弱。在这项研究中,我们确定了 1E2 对肺部 ST3 感染的疗效是否需要 FcγRIII。1E2 不能保护 FcγRIII 缺陷(FcγRIII(-/-))小鼠。对 1E2 介导作用机制的研究表明,它导致 ST3 感染的野生型(Wt [C57BL/6])小鼠肺部炎症明显减少,而在 FcγRIII(-/-)小鼠中则被消除。1E2 对 ST3 感染的 Wt、FcγRIIB(-/-)或 FcγRIII(-/-)小鼠肺部的早期细菌清除没有影响,但它降低了血培养和血清巨噬细胞炎症蛋白-2(MIP-2)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)的水平,在 Wt 和 FcγRIIB(-/-) 小鼠中,该蛋白具有保护作用。由于先前的工作表明中性粒细胞对 1E2 的疗效并不重要,我们研究了巨噬细胞是否对 1E2 针对 ST3 鼻内感染的疗效是否必需,并发现 1E2 对 Wt 小鼠鼻腔内巨噬细胞耗竭的疗效被消除。体外研究表明,1E2 促进幼稚肺泡巨噬细胞摄取 ST3,但不诱导早期细胞内杀伤。从 1E2 处理的 ST3 感染小鼠中研究的离体巨噬细胞比从 FcγRIII(-/-) 小鼠中分离的巨噬细胞显示出更多的凋亡。这些发现表明,1E2 通过影响炎症反应而不是通过诱导早期细菌清除来介导对 ST3 的保护,可能部分是通过巨噬细胞凋亡。